Search

Your search keyword '"Jakobsen, Lars"' showing total 361 results
Start Over Author "Jakobsen, Lars"
361 results on '"Jakobsen, Lars"'

3. Comparison of Outcome After Percutaneous Coronary Intervention for De Novo and In-Stent Restenosis Indications.

Author

Jakobsen, Lars, Christiansen, Evald H, Freeman, Phillip, Kahlert, Johnny, Veien, Karsten, Maeng, Michael, Ellert, Julia, Kristensen, Steen D, Christensen, Martin K, Terkelsen, Christian J, Thim, Troels, Lassen, Jens Flensted, Hougaard, Mikkel, Eftekhari, Ashkan, Jensen, Rebekka V, Støttrup, Nicolaj B, Rasmussen, Jeppe G, Junker, Anders, and Jensen, Lisette O

Published
2024
Full Text
View/download PDF

4. International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial – rationale and design

Author

Råmunddal, Truls, Holck, Emil Nielsen, Karim, Salma, Eftekhari, Ashkan, Escaned, Javier, Ioanes, Dan, Walsh, Simon, Spratt, James, Veien, Karsten, Jensen, Lisette Okkels, Tilsted, Hans-Henrik, Terkelsen, Christian Juhl, Havndrup, Ole, Olsen, Niels Thue, Kajander, Olli A., Faurie, Benjamin, Lanematt, Peep, Jakobsen, Lars, and Christiansen, Evald Høj

Published
2023
Full Text
View/download PDF

5. Optimal timing of influenza vaccination among patients with acute myocardial infarction – Findings from the IAMI trial

Author

Akhtar, Zubair, Götberg, Matthias, Erlinge, David, Christiansen, Evald H., Oldroyd, Keith G., Motovska, Zuzana, Erglis, Andrejs, Hlinomaz, Ota, Jakobsen, Lars, Engstrøm, Thomas, Jensen, Lisette O., Fallesen, Christian O., Jensen, Svend E., Angerås, Oskar, Calais, Fredrik, Kåregren, Amra, Lauermann, Jörg, Mokhtari, Arash, Nilsson, Johan, Persson, Jonas, Islam, Abu K.M.M., Rahman, Afzalur, Malik, Fazila, Choudhury, Sohel, Collier, Timothy, Pocock, Stuart J., Pernow, John, MacIntyre, Chandini R., and Fröbert, Ole

Published
2023
Full Text
View/download PDF

6. The mega COMBO collaboration: An individual patient data pooled analysis of patients undergoing PCI with COMBO stent

Author

Nardin, Matteo, Pivato, Carlo Andrea, Cao, Davide, Sartori, Samantha, Zhang, Zhongjie, Vogel, Birgit, Nicolas, Johny, Chiarito, Mauro, Qiu, Hanbo, Chandrasekhar, Jaya, Spirito, Alessandro, Abizaid, Alexandre, Christiansen, Evald Høj, Colombo, Antonio, de Winter, Robbert J., Haude, Michael, Jakobsen, Lars, Jensen, Lisette Okkels, Krucoff, Mitchell W., Landmesser, Ulf, Saito, Shigeru, Suryapranata, Harry, De Luca, Giuseppe, Dangas, George, and Mehran, Roxana

Published
2023
Full Text
View/download PDF

7. Clinical impact of influenza vaccination after ST- and non-ST-segment elevation myocardial infarction - insights from the IAMI trial

Author

Fröbert, Ole, Götberg, Matthias, Erlinge, David, Akhtar, Zubair, Christiansen, Evald H., MacIntyre, Chandini R., Oldroyd, Keith G., Motovska, Zuzana, Erglis, Andrejs, Moer, Rasmus, Hlinomaz, Ota, Jakobsen, Lars, Engstrøm, Thomas, Jensen, Lisette O., Fallesen, Christian O., Jensen, Svend E, Angerås, Oskar, Calais, Fredrik, Kåregren, Amra, Lauermann, Jörg, Mokhtari, Arash, Nilsson, Johan, Persson, Jonas, Stalby, Per, Islam, Abu K.M.M., Rahman, Afzalur, Malik, Fazila, Choudhury, Sohel, Collier, Timothy, Pocock, Stuart J., and Pernow, John

Published
2023
Full Text
View/download PDF

10. 5-Year Outcomes of PCI Guided by Measurement of Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve

Author

Götberg, Matthias, Berntorp, Karolina, Rylance, Rebecca, Christiansen, Evald H., Yndigegn, Troels, Gudmundsdottir, Ingibjörg J., Koul, Sasha, Sandhall, Lennart, Danielewicz, Mikael, Jakobsen, Lars, Olsson, Sven-Erik, Olsson, Hans, Omerovic, Elmir, Calais, Fredrik, Lindroos, Pontus, Maeng, Michael, Venetsanos, Dimitrios, James, Stefan K., Kåregren, Amra, Carlsson, Jörg, Jensen, Jens, Karlsson, Ann-Charlotte, Erlinge, David, and Fröbert, Ole

Published
2022
Full Text
View/download PDF

11. Long-term outcomes after revascularization in chronic total and non-total occluded coronary arteries: A regionwide cohort study.

Author

Holck, Emil Nielsen, Jakobsen, Lars, Winther, Naja Stausholm, Mogensen, Lone Juul-Hune, and Christiansen, Evald Høj

Subjects
*CHRONIC total occlusion, *PERCUTANEOUS coronary intervention, *VENTRICULAR ejection fraction, *MYOCARDIAL infarction, *COHORT analysis
Abstract

Background: Understanding the prognostic impact of percutaneous coronary intervention (PCI) in chronic total occlusion (CTO) is crucial for patient management. Previous studies have primarily been studying prognostic impact of successful versus unsuccessful CTO PCI. This study investigated the prognostic impact of successful and unsuccessful percutaneous coronary intervention (PCI) of chronic total occluded coronary arteries (CTO) with non-CTO PCI as reference. Methods: Patients treated with PCI from 2009 to 2019 in the Central Region of Denmark were included in a population-based cohort study. We compared successful and unsuccessful CTO PCI with non-CTO PCI. Exclusion criteria was myocardial infarction within 30 days. Primary outcome was difference in a composite major adverse cardio- and cerebrovascular events (MACCE) encompassing all-cause death, any myocardial infarction, stroke, hospitalization for heart failure or revascularization tracked via nationwide registries. Results: Of 21,141 screened patients, 10,638 were enrolled: 9,065 underwent non-CTO PCI, 1,300 had successful CTO PCI, and 273 had unsuccessful CTO PCI. Median follow-up time was 5.9 [3.5;9.0] years and 4,750 MACCEs were recorded. Compared to non-CTO PCI, the adjusted MACCE rate for successful CTO PCI was equivalent (Hazard Ratio (HR): 0.98, 95% Confidence Interval (CI): 0.90–1.07, p = 0.71). In contrast, unsuccessful CTO PCI was associated with a higher MACCE rate (HR: 1.22, 95% CI: 1.04–1.43, p<0.01). HR was adjusted for age, body-mass index, previous revascularization, smoking, kidney disease, two or three-vessel disease, left ventricular ejection fraction, diabetes and comorbidities. Conclusions: The pre-specified hypothesis was accepted. Successful CTO PCI was associated with equivalent long-term outcomes as non-CTO PCI, and unsuccessful CTO PCI was identified as a high-risk group associated to worse outcomes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Guiding early revascularization using [15O]H2O positron emission tomography myocardial perfusion imaging: impact of atrial fibrillation.

Author

Madsen, Simon, Kjaerulff, Mette Louise Gram, Ejlersen, June Anita, Nielsen, Bent Roni Ranghøj, Jakobsen, Lars, Sörensen, Jens, Tolbod, Lars Poulsen, and Gormsen, Lars Christian

Subjects
ATRIAL fibrillation diagnosis, ANGINA pectoris, EARLY medical intervention, RECEIVER operating characteristic curves, RESEARCH funding, MULTIPLE regression analysis, POSITRON emission tomography, ANGIOGRAPHY, HEMODYNAMICS, DESCRIPTIVE statistics, PERFUSION imaging, MYOCARDIAL revascularization, LONGITUDINAL method, ODDS ratio, BLOOD flow measurement, ATRIAL fibrillation, ANALYSIS of variance, PERFUSION, COMPARATIVE studies, CORONARY artery disease
Abstract

Aims Myocardial perfusion imaging (MPI) using [15O]H2O positron emission tomography (PET) is used to guide the selection of patients with angina for invasive angiography and possible revascularization. Our study evaluated (i) whether atrial fibrillation (AF) reduces global hyperaemic myocardial blood flow (MBF) and (ii) whether [15O]H2O PET MPI effectively guides revascularization procedures for patients with ongoing AF. Methods and results We prospectively recruited 346 patients with angina and persistent or paroxysmal AF referred for baseline/hyperaemic [15O]H2O PET MPI. The primary outcome was revascularization within 3 months of MPI. In the analyses, patients were divided into four groups based on whether they had ongoing AF or sinus rhythm (SR) and whether they had previously documented coronary artery disease (CAD) or not. Thus, four groups were compared: SR-noCAD, AF-noCAD, SR-CAD, and AF-CAD. Hyperaemic MBF was affected by both ongoing AF and prior CAD [MBF (mL/min/g): 2.82 (SR-noCAD) vs. 2.12 (AF-noCAD) vs. 2.22 (SR-CAD) vs. 1.80 (AF-CAD), two-way analysis of variance P < 0.0001]. In multiple linear regression, ongoing AF was independently associated with reduced hyperaemic MBF. Every 0.1 mL/min/g decrease in hyperaemic MBF was associated with a 23% increase in odds of early revascularization. Receiver operating characteristic (ROC) analysis of vessel-specific hyperaemic MBF to predict early revascularization yielded the following areas under the ROC curve: SR-noCAD: 0.95 (P < 0.0001); AF-noCAD: 0.79 (P < 0.0001); SR-CAD: 0.78 (P < 0.0001); and AF-CAD: 0.88 (P < 0.0001). Conclusion Ongoing AF is associated with 19–25% reduced global hyperaemic MBF as measured by [15O]H2O MPI PET. Regardless, vessel-specific hyperaemic MBF still predicts early revascularization in patients with AF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Early vascular healing after implantation of the polymer-free biolimus-eluting stent or the ultrathin strut biodegradable polymer sirolimus-eluting stent in patients with ST-segment elevation myocardial infarction

Author

Hansen, Kirstine N., Maeng, Michael, Antonsen, Lisbeth, Maehara, Akiko, Jakobsen, Lars, Ellert, Julia, Terkelsen, Christian J., Ahlehoff, Ole, Thim, Troels, Fallesen, Christian O., Noori, Manijeh, Veien, Karsten T., Jensen, Lisette O., and Christiansen, Evald H.

Published
2022
Full Text
View/download PDF

16. Long‐term outcomes after coronary intervention with biodegradable polymer stents in patients with acute coronary syndromes

Author

Noori, Manijeh, primary, Christiansen, Evald Høj, additional, Raungaard, Bent, additional, Junker, Anders, additional, Christensen, Martin Kirk, additional, Kahlert, Johnny, additional, Maeng, Michael, additional, Freeman, Phillip, additional, Hansen, Kirstine Nørregaard, additional, Terkelsen, Christian Juhl, additional, Ellert‐Gregersen, Julia, additional, Kristensen, Steen Dalby, additional, Veien, Karsten Tange, additional, Jakobsen, Lars, additional, and Jensen, Lisette Okkels, additional

Published
2023
Full Text
View/download PDF

17. Influenza Vaccination After Myocardial Infarction: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

Author

Fröbert, Ole, Götberg, Matthias, Erlinge, David, Akhtar, Zubair, Christiansen, Evald H., MacIntyre, Chandini R., Oldroyd, Keith G., Motovska, Zuzana, Erglis, Andrejs, Moer, Rasmus, Hlinomaz, Ota, Jakobsen, Lars, Engstrøm, Thomas, Jensen, Lisette O., Fallesen, Christian O., Jensen, Svend E, Angerås, Oskar, Calais, Fredrik, Kåregren, Amra, Lauermann, Jörg, Mokhtari, Arash, Nilsson, Johan, Persson, Jonas, Stalby, Per, Islam, Abu K.M.M., Rahman, Afzalur, Malik, Fazila, Choudhury, Sohel, Collier, Timothy, Pocock, Stuart J., and Pernow, John

Published
2021
Full Text
View/download PDF

19. TCT-418 Impact of Diabetes on Clinical Outcomes After Percutaneous Coronary Intervention: 5-Year Results of the SORTOUT IX Trial Comparing the Polymer-Free Biolimus A9-Coated Stent to the Ultra-Thin Strut Biodegradable Polymer Sirolimus-Eluting Stent

Author

Hansen, Kirstine, primary, Christiansen, Evald, additional, Ellert, Julia, additional, Eftekhari, Ashkan, additional, Jakobsen, Lars, additional, Veien, Karsten, additional, Freeman, Phillip, additional, Jensen, Rebekka Vibjerg, additional, Noori, Manijeh, additional, Støttrup, Nicolaj, additional, Junker, Anders, additional, Trøan, Jens, additional, Maeng, Michael, additional, Terkelsen, Christian, additional, Raungaard, Bent, additional, Lassen, Jens, additional, and Jensen, Lisette Okkels, additional

Published
2023
Full Text
View/download PDF

20. TCT-708 5-Year Outcomes of Patients With Diabetes Mellitus Treated With a Sirolimus-Eluting or a Biolimus-Eluting Stent With Biodegradable Polymer: From the SORT OUT VII Trial

Author

Trøan, Jens, primary, Christiansen, Evald, additional, Hansen, Kirstine Norregaard, additional, Eftekhari, Ashkan, additional, Jakobsen, Lars, additional, Maeng, Michael, additional, Freeman, Phillip, additional, Jensen, Rebekka Vibjerg, additional, Christensen, Martin Kirk, additional, Noori, Manijeh, additional, Veien, Karsten, additional, Støttrup, Nicolaj, additional, Ellert, Julia, additional, and Jensen, Lisette, additional

Published
2023
Full Text
View/download PDF

21. TCT-669 Impact of Acute Coronary Syndromes on Long-Term Clinical Outcomes After Percutaneous Coronary Intervention With the Biolimus-Coated BioFreedom Stent or Biodegradable Polymer Sirolimus-Eluting Orsiro Stent: From the SORT OUT IX Trial

Author

Noori, Manijeh, primary, Christiansen, Evald, additional, Veien, Karsten, additional, Eftekhari, Askhan, additional, Jakobsen, Lars, additional, Ellert, Julia, additional, Jensen, Rebekka Vibjerg, additional, Hansen, Kirstine, additional, Støttrup, Nicolaj, additional, Freeman, Phillip, additional, Junker, Anders, additional, Terkelsen, Christian, additional, Jensen, Svend Eggert, additional, Maeng, Michael, additional, Lassen, Jens, additional, and Jensen, Lisette Okkels, additional

Published
2023
Full Text
View/download PDF

25. Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes

Author

Escaned, Javier, Ryan, Nicola, Mejía-Rentería, Hernán, Cook, Christopher M., Dehbi, Hakim-Moulay, Alegria-Barrero, Eduardo, Alghamdi, Ali, Al-Lamee, Rasha, Altman, John, Ambrosia, Alphonse, Baptista, Sérgio B., Bertilsson, Maria, Bhindi, Ravinay, Birgander, Mats, Bojara, Waldemar, Brugaletta, Salvatore, Buller, Christopher, Calais, Fredrik, Silva, Pedro Canas, Carlsson, Jörg, Christiansen, Evald H., Danielewicz, Mikael, Di Mario, Carlo, Doh, Joon-Hyung, Erglis, Andrejs, Erlinge, David, Gerber, Robert T., Going, Olaf, Gudmundsdottir, Ingibjörg, Härle, Tobias, Hauer, Dario, Hellig, Farrel, Indolfi, Ciro, Jakobsen, Lars, Janssens, Luc, Jensen, Jens, Jeremias, Allen, Kåregren, Amra, Karlsson, Ann-Charlotte, Kharbanda, Rajesh K., Khashaba, Ahmed, Kikuta, Yuetsu, Krackhardt, Florian, Koo, Bon-Kwon, Koul, Sasha, Laine, Mika, Lehman, Sam J., Lindroos, Pontus, Malik, Iqbal S., Maeng, Michael, Matsuo, Hitoshi, Meuwissen, Martijn, Nam, Chang-Wook, Niccoli, Giampaolo, Nijjer, Sukhjinder S., Olsson, Hans, Olsson, Sven-Erik, Omerovic, Elmir, Panayi, Georgios, Petraco, Ricardo, Piek, Jan J., Ribichini, Flavo, Samady, Habib, Samuels, Bruce, Sandhall, Lennart, Sapontis, James, Sen, Sayan, Seto, Arnold H., Sezer, Murat, Sharp, Andrew S.P., Shin, Eun-Seok, Singh, Jasvindar, Takashima, Hiroaki, Talwar, Suneel, Tanaka, Nobuhiro, Tang, Kare, Van Belle, Eric, van Royen, Niels, Varenhorst, Christoph, Vinhas, Hugo, Vrints, Christiaan J., Walters, Darren, Yokoi, Hiroyoshi, Fröbert, Ole, Patel, Manesh R., Serruys, Patrick, Davies, Justin E., and Götberg, Matthias

Published
2018
Full Text
View/download PDF

32. Myocardial Flow Reserve, an Independent Prognostic Marker of All-Cause Mortality Assessed by 82 Rb PET Myocardial Perfusion Imaging: A Danish Multicenter Study

Author

Højstrup, Signe, primary, Hansen, Kim W., additional, Talleruphuus, Ulrik, additional, Marner, Lisbeth, additional, Bjerking, Louise, additional, Jakobsen, Lars, additional, Christiansen, Evald H., additional, Bouchelouche, Kirsten, additional, Wiinberg, Niels, additional, Guldbrandsen, Kasper, additional, Galatius, Søren, additional, and Prescott, Eva, additional

Published
2023
Full Text
View/download PDF

33. Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study

Author

Thim, Troels, primary, Jakobsen, Lars, additional, Jensen, Rebekka Vibjerg, additional, Støttrup, Nicolaj, additional, Eftekhari, Ashkan, additional, Grove, Erik Lerkevang, additional, Larsen, Sanne Bøjet, additional, Sørensen, Jacob Thorsted, additional, Carstensen, Steen, additional, Amiri, Sahar, additional, Veien, Karsten Tange, additional, Christiansen, Evald Høj, additional, Terkelsen, Christian Juhl, additional, Maeng, Michael, additional, and Kristensen, Steen Dalby, additional

Published
2023
Full Text
View/download PDF

36. Long‐term outcomes after coronary intervention with biodegradable polymer stents in patients with acute coronary syndromes.

Author

Noori, Manijeh, Christiansen, Evald Høj, Raungaard, Bent, Junker, Anders, Christensen, Martin Kirk, Kahlert, Johnny, Maeng, Michael, Freeman, Phillip, Hansen, Kirstine Nørregaard, Terkelsen, Christian Juhl, Ellert‐Gregersen, Julia, Kristensen, Steen Dalby, Veien, Karsten Tange, Jakobsen, Lars, and Jensen, Lisette Okkels

Published
2024
Full Text
View/download PDF

38. Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention: The SORT OUT IX Trial

Author

Jensen, Lisette Okkels, Maeng, Michael, Raungaard, Bent, Kahlert, Johnny, Ellert, Julia, Jakobsen, Lars, Villadsen, Anton Boel, Veien, Karsten Tange, Kristensen, Steen Dalby, Ahlehoff, Ole, Carstensen, Steen, Christensen, Martin Kirk, Terkelsen, Christian Juhl, Engstroem, Thomas, Hansen, Knud Nørregaard, Bøtker, Hans Erik, Aaroe, Jens, Thim, Troels, Thuesen, Leif, Freeman, Philip, Aziz, Ahmed, Eftekhari, Ashkan, Junker, Anders, Jensen, Svend Eggert, Lassen, Jens Flensted, Hansen, Henrik Steen, and Christiansen, Evald Høj

Published
2020
Full Text
View/download PDF

39. Coronary Microvascular Disease Assessed by 82-Rubidium Positron Emission Tomography Myocardial Perfusion Imaging Is Associated With Small Vessel Disease of the Kidney and Brain

Author

Højstrup, Signe, Hansen, Kim W, Talleruphuus, Ulrik, Marner, Lisbeth, Galatius, Søren, Rauf, Maira, Bjerking, Louise H, Jakobsen, Lars, Christiansen, Evald H, Bouchelouche, Kirsten, Christensen, Hanne, and Prescott, Eva I B

Subjects
Male, Stroke Volume, Rubidium, Brain/diagnostic imaging, Ventricular Function, Left, Myocardial Perfusion Imaging/methods, Cohort Studies, Positron-Emission Tomography, Coronary Circulation, Humans, Female, Vascular Diseases, Kidney/diagnostic imaging, Aged, Coronary Artery Disease/diagnostic imaging, Microvascular Angina
Abstract

Background Coronary microvascular disease (CMD) may be part of a systemic small vessel disease that also manifests as neurological impairment and kidney disease. However, clinical evidence supporting a potential link is scarce. We assessed whether CMD is associated with an increased risk of small vessel disease in the kidney and brain. Methods and Results A retrospective multicenter (n=3) study of patients clinically referred to 82-rubidium positron emission tomography myocardial perfusion imaging was conducted between January 2018 and August 2020. Exclusion criterion was reversible perfusion defects >5%. CMD was defined as myocardial flow reserve (MFR) ≤2. The primary outcome, microvascular event, was defined by hospital contact for chronic kidney disease, stroke, or dementia. Among 5122 patients, 51.7% were men, median age 69.0 [interquartile range, 60.0-75.0] years, 11.0% had left ventricular ejection fraction ≤40%, and 32.4% had MFR ≤2. MFR was associated with baseline estimated glomerular filtration rate after multivariable adjustment (β=0.04 [95% CI, 0.03-0.05]; P2 (11.6% versus 5.5%, P

Published
2023

40. Outcomes After Complex PCI With COMBO Stent Implantation: Insights from a Real-World Pooled Dataset

Author

Spirito, Alessandro, Nussbaum, Jeremy, Sartori, Samantha, Vogel, Birgit, Abizaid, Alexandre, Cao, Davide, Christiansen, Evald Høj, Colombo, Antonio, de Winter, Robbert J., Haude, Michael, Kamaleldin, Karim, Jakobsen, Lars, Jensen, Lisette Okkels, Krucoff, Mitchell W., Landmesser, Ulf, Nardin, Matteo, Saito, Shigeru, Smith, Kenneth F., Suryapranata, Harry, De Luca, Giuseppe, Dangas, George, and Mehran, Roxana

Published
2023
Full Text
View/download PDF

41. Clinical impact of influenza vaccination after ST- and non-ST-segment elevation myocardial infarction - from the IAMI trial

Author

Froebert, Ole, Goetberg, Matthias, Erlinge, David, Akhtar, Zubair, Christiansen, Evald H., MacIntyre, Chandini R., Oldroyd, Keith G., Motovska, Zuzana, Erglis, Andrejs, Moer, Rasmus, Hlinomaz, Ota, Jakobsen, Lars, Engstrom, Thomas, Jensen, Lisette O., Fallesen, Christian O., Jensen, Svend E., Angeras, Oskar, Calais, Fredrik, Karegren, Amra, Lauermann, Jörg, Mokhtari, Arash, Nilsson, Johan, Persson, Jonas, Stalby, Per, Islam, Abu K. M. M., Rahman, Afzalur, Malik, Fazila, Choudhury, Sohel, Collier, Timothy, Pocock, Stuart J., Pernow, John, Froebert, Ole, Goetberg, Matthias, Erlinge, David, Akhtar, Zubair, Christiansen, Evald H., MacIntyre, Chandini R., Oldroyd, Keith G., Motovska, Zuzana, Erglis, Andrejs, Moer, Rasmus, Hlinomaz, Ota, Jakobsen, Lars, Engstrom, Thomas, Jensen, Lisette O., Fallesen, Christian O., Jensen, Svend E., Angeras, Oskar, Calais, Fredrik, Karegren, Amra, Lauermann, Jörg, Mokhtari, Arash, Nilsson, Johan, Persson, Jonas, Stalby, Per, Islam, Abu K. M. M., Rahman, Afzalur, Malik, Fazila, Choudhury, Sohel, Collier, Timothy, Pocock, Stuart J., and Pernow, John

Abstract

Background Influenza vaccination early after myocardial infarction (MI) improves prognosis but vaccine effectiveness may differ dependent on type of MI. Methods A total of 2,571 participants were prospectively enrolled in the Influenza vaccination after myocardial infarction (IAMI) trial and randomly assigned to receive in-hospital inactivated influenza vaccine or saline placebo. The trial was conducted at 30 centers in eight countries from October 1, 2016 to March 1, 2020. Here we report vaccine effective-ness in the 2,467 participants with ST-segment elevation MI (STEMI, n = 1,348) or non-ST-segment elevation MI (NSTEMI, n = 1,119). The primary endpoint was the composite of all-cause death, MI, or stent thrombosis at 12 months. Cumulative incidence of the primary and key secondary endpoints by randomized treatment and NSTEMI/STEMI was estimated using the Kaplan-Meier method. Treatment effects were evaluated with formal interaction testing to assess for effect modification. Results Baseline risk was higher in participants with NSTEMI. In the NSTEMI group the primary endpoint occurred in 6.5% of participants assigned to influenza vaccine and 10.5% assigned to placebo (hazard ratio [HR], 0.60; 95% CI, 0.39-0.91), compared to 4.1% assigned to influenza vaccine and 4.5% assigned to placebo in the STEMI group (HR, 0.90; 95% CI, 0.54-1.50, P = .237 for interaction). Similar findings were seen for the key secondary endpoints of all-cause death and cardiovascular death. The Kaplan-Meier risk difference in all-cause death at one year was more pronounced in participants with NSTEMI (NSTEMI: HR, 0.47; 95% CI 0.28-0.80, STEMI: HR, 0.86; 95% CI, 0.43-1.70, interaction P = .028). Conclusions The beneficial effect of influenza vaccination on adverse cardiovascular events may be enhanced in patients with NSTEMI compared to those with STEMI., Funding Agencies|Swedish Heart-Lung Foundation [20150284]; Danish Heart Foundation [16-R107-A6596-22958]; ALF Grants; Nyckelfonden; Region Orebro, Sweden; SanofiPasteurr, Lyon, France

Published
2023
Full Text
View/download PDF

42. Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial

Author

Hansen, Kirstine Nørregaard, primary, Jensen, Lisette Okkels, additional, Maeng, Michael, additional, Christensen, Martin Kirk, additional, Noori, Manijeh, additional, Kahlert, Johnny, additional, Jakobsen, Lars, additional, Junker, Anders, additional, Freeman, Phillip, additional, Ellert-Gregersen, Julia, additional, Raungaard, Bent, additional, Terkelsen, Christian Juhl, additional, Veien, Karsten Tange, additional, and Christiansen, Evald Høj, additional

Published
2023
Full Text
View/download PDF

44. Impact of acute coronary syndrome on clinical outcomes after revascularization with the dual‐therapy CD34 antibody‐covered sirolimus‐eluting Combo stent and the sirolimus‐eluting Orsiro stent

Author

Jakobsen, Lars, primary, Christiansen, Evald H., additional, Freeman, Phillip, additional, Kahlert, Johnny, additional, Veien, Karsten, additional, Maeng, Michael, additional, Raungaard, Bent, additional, Ellert, Julia, additional, Kristensen, Steen D., additional, Christensen, Martin K., additional, Terkelsen, Christian J., additional, Thim, Troels, additional, Eftekhari, Ashkan, additional, Jensen, Rebekka V., additional, Støttrup, Nicolaj B., additional, Junker, Anders, additional, Hansen, Henrik S., additional, and Jensen, Lisette O., additional

Published
2022
Full Text
View/download PDF

45. Evaluation of Coronary Artery Stenosis by Quantitative Flow Ratio During Invasive Coronary Angiography: The WIFI II Study (Wire-Free Functional Imaging II)

Author

Westra, Jelmer, Tu, Shengxian, Winther, Simon, Nissen, Louise, Vestergaard, Mai-Britt, Andersen, Birgitte Krogsgaard, Holck, Emil Nielsen, Fox Maule, Camilla, Johansen, Jane Kirk, Andreasen, Lene Nyhus, Simonsen, Jo Krogsgaard, Zhang, Yimin, Kristensen, Steen Dalby, Maeng, Michael, Kaltoft, Anne, Terkelsen, Christian Juhl, Krusell, Lars Romer, Jakobsen, Lars, Reiber, Johan H.C., Lassen, Jens Flensted, Bøttcher, Morten, Bøtker, Hans Erik, Christiansen, Evald Høj, and Holm, Niels Ramsing

Published
2018
Full Text
View/download PDF

46. Randomized comparison of sirolimus eluting, and biolimus eluting bioresorbable polymer stents: the SORT-OUT VII optical coherence tomography study

Author

Andreasen, Lene N, Holm, Niels R, Balleby, Ida R, Krusell, Lars R, Maeng, Michael, Jakobsen, Lars, Veien, Karsten T, Hansen, Knud N, Kristensen, Steen D, Hjort, Jakob, Kaltoft, Anne, Dijkstra, Jouke, Terkelsen, Christian J, Lassen, Jens F, Madsen, Morten, Bøtker, Hans Erik, Jensen, Lisette O, and Christiansen, Evald H

Published
2018
Full Text
View/download PDF

47. Myocardial Flow Reserve, an Independent Prognostic Marker of All-Cause Mortality Assessed by 82Rb PET Myocardial Perfusion Imaging: A Danish Multicenter Study.

Author

Højstrup, Signe, Hansen, Kim W., Talleruphuus, Ulrik, Marner, Lisbeth, Bjerking, Louise, Jakobsen, Lars, Christiansen, Evald H., Bouchelouche, Kirsten, Wiinberg, Niels, Guldbrandsen, Kasper, Galatius, Søren, and Prescott, Eva

Abstract

BACKGROUND: Rubidium-82 positron emission tomography (82Rb PET) myocardial perfusion imaging is used in clinical practice to quantify regional perfusion defects. Additionally, 82Rb PET provides a measure of absolute myocardial flow reserve (MFR), describing the vasculature state of health. We assessed whether 82Rb PET-derived MFR is associated with all-cause mortality independently of the extent of perfusion defects. METHODS: We conducted a multicenter clinical registry-based study of patients undergoing 82Rb PET myocardial perfusion imaging on suspicion of chronic coronary syndromes. Patients were followed up in national registries for the primary outcome of all-cause mortality. Global MFR =2 was considered reduced. RESULTS: Among 7169 patients studied, 38.1% were women, the median age was 69 (IQR, 61-76) years, and 39.0% had MFR =2. A total of 667 (9.3%) patients died during a median follow-up of 3.1 (IQR, 2.6-4.0) years, more in patients with MFR =2 versus MFR >2 (15.7% versus 5.2%; P<0.001). MFR =2 was associated with all-cause mortality across subgroups defined by the extent of perfusion defects (all P<0.05). In a Cox survival regression model adjusting for sex, age, comorbidities, kidney function, left ventricular ejection fraction, and perfusion defects, MFR =2 was a robust predictor of mortality with a hazard ratio of 1.62 (95% CI, 1.31-2.02; P<0.001). Among patients with no reversible perfusion defects (n=3101), MFR =2 remained strongly associated with mortality (hazard ratio, 1.86 [95% CI, 1.26-2.73]; P<0.01). The prognostic value of impaired MFR was similar for cardiac and noncardiac death. CONCLUSIONS: MFR =2 predicts all-cause mortality independently of the extent of perfusion defects. Our results support the inclusion of MFR when assessing the prognosis of patients suspected of chronic coronary syndromes. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Polymer-free biolimus-coated stents versus ultrathin-strut biodegradable polymer sirolimus-eluting stents: two-year outcomes of the randomised SORT OUT IX trial

Author

Ellert-Gregersen, Julia, primary, Jensen, Lisette Jensen, additional, Jakobsen, Lars, additional, Freeman, Phillip Michael, additional, Eftekhari, Ashkan, additional, Maeng, Michael, additional, Raungaard, Bent, additional, Engstroem, Thomas, additional, Kahlert, Johnny, additional, Hansen, Henrik Hansen, additional, and Christiansen, Evald Høj, additional

Published
2022
Full Text
View/download PDF

50. Impact of diabetes on 1-year clinical outcome in patients undergoing revascularization with the BioFreedom stents or the Orsiro stents from the SORT OUT IX trial

Author

Hansen, Kirstine Nørregaard, Maeng, Michael, Raungaard, Bent, Engstrøm, Thomas, Veien, Karsten Tange, Kristensen, Steen Dalby, Ellert-Gregersen, Julia, Jensen, Svend Eggert, Junker, Anders, Kahlert, Johnny, Jakobsen, Lars, Christiansen, Evald Høj, Jensen, Lisette Okkels, Hansen, Kirstine Nørregaard, Maeng, Michael, Raungaard, Bent, Engstrøm, Thomas, Veien, Karsten Tange, Kristensen, Steen Dalby, Ellert-Gregersen, Julia, Jensen, Svend Eggert, Junker, Anders, Kahlert, Johnny, Jakobsen, Lars, Christiansen, Evald Høj, and Jensen, Lisette Okkels

Abstract

This sub-study of the SORT OUT IX trial sought to compare clinical outcomes between patients with diabetes randomized to implantation of either the polymer-free biolimus A9-coated BioFreedom stent (BF-BES) or the ultra-thin strut, biodegradable polymer sirolimus-eluting Orsiro stent (O-SES). Patients with diabetes have an increased risk of target lesion failure (TLF) after percutaneous coronary intervention (PCI). The impact of different stent types in patients with diabetes is still discussed. A total of 607 of the 3151 patients (19.3%) enrolled in the SORT OUT IX study had diabetes. Randomization was stratified by patients with/without diabetes; 304 received BF-BES and 303 O-SES. The primary endpoint was TLF, which was a composite of cardiac death, myocardial infarction (not related to other than the index lesion) and target lesion revascularization (TLR) within 1 year. After 1 year, patients with diabetes had higher TLF (7.2% vs. 3.7%, incidence rate ratio [IRR]: 1.65; 95% confidence interval [CI]: 1.08–2.50), than patients without diabetes. TLF did not differ significantly between BF-BES and O-SES in patients with diabetes (8.2% vs. 6.3%, IRR: 1.17; 95% CI: 0.63–2.20). In patients with diabetes, cardiac death occurred in 2.3% of BF-BES and in 3.6% of O-SES (IRR: 0.58; 95% CI: 0.23–1.45) and TLR occurred in 5.3% and 2.3% of BF-BES and O-SES, respectively (IRR: 2.12; 95% CI: 0.81–5.56). Definite stent thrombosis rates of 1.3% were found in both stent types. Patients with diabetes had higher 1-year TLF rate after PCI compared to patients without diabetes, whereas TLF did not differ significantly between the two stent types BF-BES and O-SES in patients with diabetes.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results